CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 67 enrolled
Drug / intervention
Medtronic or Vitatron Dual-Chamber Pacemaker +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00949715
NCT00949715N/ACompleted
CompareCT.gov

Optimize RV Follow-up Selective Site Pacing Clinical Trial

Medtronic Cardiac Rhythm and Heart Failure·interventional·Posted Jul 30, 2009·Updated Feb 15, 2018

In Brief

A clinical study evaluating Medtronic or Vitatron Dual-Chamber Pacemaker and Medtronic SelectSecure 3830 Lead for Cardiac Pacing and 2 related conditions. Completed, enrolled 67 participants across 12 sites in 3 countries.

Detailed Summary

The purpose of the Optimize RV Follow-Up study is to determine the long-term effect of selective site pacing. Selective site pacing refers to which area of the right ventricle the lead is placed. The goal of selective site pacing is to improve how the heart contracts when paced.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiac Pacing, Right Ventricular Pacing, Left Ventricular Ejection Fraction
CountriesIsrael, Italy, United States
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 30, 2009
Enrollment StartSep 1, 2009
Primary CompletionApr 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 16.9 years ago

Interventions

Medtronic or Vitatron Dual-Chamber Pacemakerdevice

A Medtronic or Vitatron market-approved dual-chamber implantable pulse generator (IPG) with atrial tachycardia/atrial fibrillation (AT/AF) trending ability

Medtronic SelectSecure 3830 Leaddevice

Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead